Compare MKSI & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKSI | ASND |
|---|---|---|
| Founded | 1961 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 17.7B |
| IPO Year | 1997 | 2014 |
| Metric | MKSI | ASND |
|---|---|---|
| Price | $231.50 | $239.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | $263.31 | ★ $281.50 |
| AVG Volume (30 Days) | ★ 1.2M | 444.6K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | ★ 55.52 | N/A |
| EPS | ★ 3.60 | N/A |
| Revenue | ★ $3,931,000,000.00 | N/A |
| Revenue This Year | $15.87 | $96.35 |
| Revenue Next Year | $10.87 | $44.91 |
| P/E Ratio | $74.25 | ★ N/A |
| Revenue Growth | ★ 9.62 | N/A |
| 52 Week Low | $115.74 | $186.05 |
| 52 Week High | $447.62 | $282.15 |
| Indicator | MKSI | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 57.88 |
| Support Level | $241.86 | $213.28 |
| Resistance Level | $247.12 | $282.15 |
| Average True Range (ATR) | 8.37 | 7.49 |
| MACD | 1.41 | 0.53 |
| Stochastic Oscillator | 10.66 | 73.36 |
MKS Inc delivers foundational technology solutions for leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. The company provides instruments, components, subsystems, systems, process control solutions, and specialty chemicals technology that improve process performance and optimize productivity. Its solutions address challenges of miniaturization and complexity in device manufacturing, enabling increased power, speed, and feature enhancement. MKS Inc operates through three divisions: Vacuum Solutions Division (VSD), Photonics Solutions Division (PSD), and Materials Solutions Division (MSD). The company operates in the United States, which generates maximum revenue, as well as China and other countries.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.